ARCHIVES

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: NIDR, NCI award $2.8 Million In Grants For Oral Cancer research Centers

October 4, 1996

FDA Oncology Unit Fastest in Approvals Despite Having Highest Workload

May 9, 2014

In Brief: ACCC Celebrates 25th: James Hospital Receives Large Donations

April 9, 1999

FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say

January 26, 1996

Breast Treatment Component Will Be Planned for WHI

June 21, 1991

Cyclamate Review Committee Starts Survey; Inventor Castigates NCI

September 12, 1975